Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded rinse containing glycopyrrolate hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing glycopyrrolate are listed in injection, tablet, solution, aerosol, liquid and cloth forms. No finished glycopyrrolate product of any kind is listed in rinse form.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Glycopyrrolate is an anticholinergic that reduces secretions and sweating, commonly compounded into topical creams, wipes and solutions and oral liquids.
Glycopyrrolate (glycopyrronium) is a synthetic anticholinergic. It blocks acetylcholine at muscarinic receptors in smooth muscle and secretory glands, which cuts down saliva, airway secretions, stomach acid and sweat. Because it is a quaternary ammonium compound it does not cross the blood-brain barrier, so drowsiness and confusion are less likely than with older anticholinergics. Manufactured forms include glycopyrrolate tablets, FDA-approved as an adjunct for peptic ulcer symptoms in adults; Cuvposa oral solution for severe drooling in children with neurologic conditions; Qbrexza topical cloth for primary axillary hyperhidrosis; injection for perioperative use; and inhaled products for COPD. Prescribers order glycopyrrolate compounded when they want a topical cream or solution for areas other than the underarm, a lower or intermediate oral strength, or a liquid for adults who cannot swallow tablets. Compounded preparations are not FDA-approved and require a prescription.
The manufactured labels carry no boxed warning. Glycopyrrolate is contraindicated in glaucoma, urinary obstruction including prostate enlargement, bowel obstruction or severe motility disorders, toxic megacolon, severe ulcerative colitis, myasthenia gravis and unstable heart conditions. It reduces sweating, so overheating and heat stroke can occur in hot weather or during exercise; stop and talk to your prescriber or pharmacist if you are not sweating when you should be. Other anticholinergics such as tricyclic antidepressants, antispasmodics and amantadine add to its effects, and solid potassium chloride tablets should not be combined with it. The tablet label advises against use in adults 65 and older because of urinary retention, delirium and falls. Topical cloths can dilate the pupil if the drug reaches the eye, so wash hands after use. Pregnancy: no human data; animal studies showed no fetal harm. Breastfeeding: no milk data; long-term oral use may reduce milk supply. Common side effects are dry mouth, blurred vision, constipation and trouble urinating.
Glycopyrrolate is a quaternary amine competitive muscarinic antagonist with minimal CNS or placental penetration. After intravenous dosing the elimination half-life is about 50 minutes with a 2 to 4 hour duration; elimination is predominantly renal, and uremic patients show markedly reduced excretion, so anticholinergic effects should be monitored in renal impairment. The oral tablet label reports no bioavailability figure. Systemic exposure from the topical cloth is low with no accumulation. Labeled indications by product: glycopyrrolate tablets (adjunct for peptic ulcer in adults), Cuvposa (chronic severe drooling in pediatric neurologic conditions), Qbrexza (primary axillary hyperhidrosis, age 9 and up), injection (perioperative secretion control, vagal blockade, reversal of neuromuscular blockade with neostigmine), inhaled glycopyrrolate (COPD). Prescribers have ordered compounded topical glycopyrrolate creams and solutions for localized hyperhidrosis at sites other than the axilla; IJPC published a glycopyrrolate cream formulation in 2001 and a 2022 case letter describes a compounded glycopyrronium preparation for residual-limb hyperhidrosis. Dosing is per prescriber. Monitor heart rate, hydration and heat exposure, urinary retention, bowel function and mental status in older patients. Not a controlled substance.
Measure the amount shown on your label with the cup or syringe provided. Swish it around your mouth for the time on your label, often 30 seconds or longer, then spit it out unless your label says to swallow. Do not eat, drink or rinse with water for a while afterward as directed. Shake the bottle first if your label says to.
Oral rinses are aqueous. Under USP <795>, a preserved rinse usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Swish in mouth, hold as directed and then expectorate
